Ad Nauseam

With new forays into sponsored content, pharmaceutical companies are rewriting the script for direct-to-consumer advertising.  When U.S. consumers settle in to watch their favorite TV program, they are accustomed to sitting through commercial breaks featuring...

Online Exclusives

Private-Sector Funding Presents Ethical Problems for NIH

To strengthen funding for the National Institutes of Health (NIH) in the 1990s, U.S. Congress created the Foundation of the National Institutes of Health...

Pharmaceutical Lobbying Group Funnels “Dark Money” to Sway Policy

An investigation by Kaiser Health News revealed that the Pharmaceutical Research and Manufacturers of America (PhRMA) quietly gave millions of dollars to groups that...

News

From the Blood Journals

WIB_icon

Researchers Identify Cancer Gene Mutations Linked to Poor Outcomes in CML

Despite the good outcomes experienced by most patients with chronic-phase chronic myeloid leukemia (CP-CML) treated with tyrosine kinase inhibitors (TKIs), a susbset do not...
WIB_icon

Risk-Adapted, Chemotherapy-Alone Treatment Strategy Effective for Early-Stage Hodgkin Lymphoma

Detection of disease on interim PET/CT scans after two cycles of chemotherapy is a powerful predictor of outcomes in patients with early-stage, non-bulky Hodgkin...

Multimedia

Pulling Back the Curtain: Allison Rosenthal, DO

Hear more from our interview with Dr. Rosenthal, where she talks about the best career advice she's ever received and the best (and worst) parts of...
video

Expanding Acalabrutinib to Waldenström Macroglobulinemia

Roger Owen, MRCP, MRCPath, MD, presents phase II data of the selective Bruton tyrosine kinase inhibitor, which showed “exceptional response rates” in both treatment-naïve...
video

Weekly Carfilzomib Dosing Superior to Twice-Weekly Dosing

James Berenson, MD, discusses results from a trial evaluating less-frequent dosing of carfilzomib for patients with myeloma. Once-weekly dosing was superior, but the mechanisms...
video

Enhancing Ibrutinib With Rituximab in Waldenström Macroglobulinemia

Combining ibrutinib with rituximab led to longer progression-free survival, compared with ibrutinib alone, in patients with Waldenström macroglobulinemia. Meletios Dimopoulos, MD, shares results from...

On Location

CheckMate 205: Evaluating Nivolumab in Newly Diagnosed Hodgkin Lymphoma

In a study presented by Radhakrishnan Ramchandren, MD, at the 23rd Congress of the European...

Better Together: IDH Inhibitors Plus Azacitidine in Newly Diagnosed AML

Results from a phase Ib/II study presented at the 23rd Congress of the European Hematology...

Cardiac Biomarkers Predict Quality of Life in Patients With Light-Chain Amyloidosis

In a study presented at the 23rd Congress of the European Hematology Association, researchers demonstrated...

Combining Ibrutinib and Venetoclax Produces High MRD-Negative Rates in Treatment-Naïve CLL

The all-oral regimen of single-agent ibrutinib followed by combined ibrutinib and venetoclax increased the odds...

Bispecific Antibody AMV564 Active in Relapsed and Refractory AML

Treatment with the CD33/CD3 bivalent, bispecific antibody AMV564 demonstrated clinical activity in patients with relapsed...

Updated Results from JULIET: Tisagenlecleucel Associated With Durable Responses in DLBCL

In May 2018, the U.S. Food and Drug Administration expanded the approval of the chimeric...

Latest Headlines

Advertisement

ASH Directions

Mehdi Hamadani Named Editor of ASH News Daily 2018, and more

Mehdi Hamadani Named Editor of ASH News Daily 2018  Mehdi Hamadani, MD, has been named the 2018 Editor-in- Chief of ASH News Daily, the official...

A Call to Action on Hematology and Aging, ASH Clinical News Wins Award of...

A Call to Action on Hematology and Aging The Journal of Geriatric Oncology has published a report by lead author Ashley E. Rosko, MD, from...

Sign up for our
eNewsletter!

Fred Hutch Scientists Receive $20 Million for Leukemia Projects, and more

Remembering Alan Rabson (1926 – 2018)Alan Rabson, MD, a long-time leader at the National Cancer Institute (NCI), passed away on July 4, 2018, at...

American Cancer Society Awards $2.6 Million for Immunotherapy Research, and more

Remembering Past ASH President George Stamatoyannopoulos (1934 - 2018) George Stamatoyannopoulos, MD, DrSci, a professor of medical genetics at the University of Washington who pioneered...

Vijay Sankaran Receives Weill Cornell’s Children’s Health Research Award, Scripps Researchers Receive Nearly $3...

Remembering Frank “Len” Johnson (1945 - 2017)  Frank Leonard “Len” Johnson, MD, a pediatric hematologist/oncologist, passed away on December 24, 2017, after a brief illness. Growing...

Ad Nauseam

With new forays into sponsored content, pharmaceutical companies are rewriting the script for direct-to-consumer advertising.  When U.S. consumers settle in to watch their favorite TV...

MOC Machinations

The changing landscape of MOC Knowledge Check-Ins and how the American Society of Hematology continues pursuing a pragmatic approach to the MOC process.  The past...

Leveling the Playing Field: Can We Achieve Gender Equality in Medicine?

When Stephanie Abbuhl, MD, professor of emergency medicine at the University of Pennsylvania Perelman School of Medicine, was growing up in the early 1960s,...